Full Breakdown
Grifols Faces Regulatory Scrutiny After Plasma Donor Deaths in Canada
4/2/2026, 8:09:59 PM
Overview of Regulatory Actions
Spanish pharmaceutical company Grifols SA is under scrutiny from Health Canada following the deaths of two plasma donors at its Winnipeg collection centers. Health Canada has imposed new terms and conditions on Grifols' blood establishment license, citing "recurring, systemic deficiencies" across multiple sites. These restrictions affect all 16 of Grifols' plasma collection centers in Canada, including those in Calgary and Regina, and will remain until the company demonstrates compliance with health regulations.
Details of the Incidents
The two fatalities occurred less than four months apart, with one reported on October 25, 2025, involving 22-year-old Rodiyat Alabede, and another on January 30, 2026, at a different Grifols location. Health Canada has stated that its investigations have not established a direct link between the plasma donation process and the deaths. However, the regulator has identified significant operational deficiencies, including inadequate donor assessments and insufficiently trained staff.
Health Canada's Findings
Health Canada's inspections revealed that Grifols failed to properly validate and maintain critical equipment, did not accurately assess donor suitability, and allowed donors to give plasma despite potential safety concerns. The agency has mandated that Grifols reduce appointment numbers to ensure staff can adhere to procedures and improve oversight of new employees. Additionally, the company must conduct annual audits of its operations and submit these findings to Health Canada.
Official Statements & Responses
Mary Hughes, Grifols' vice president of sales in Canada, testified before lawmakers that there is "no correlation between death and plasma collection." She emphasized that donors are informed about the risks associated with plasma donation. In response to the regulatory actions, Hughes stated, "We have submitted and implemented comprehensive corrective action plans."
Criticism & Opposition
The Canadian Health Coalition, a public health advocacy group, has called for Grifols to cease operations in Canada, arguing that the company’s practices pose risks to public health. Spokesperson Anne Lagacé Dowson criticized the partnership between Grifols and Canadian Blood Services, suggesting that the contract should be annulled in favor of a non-profit model for plasma collection.
Conflicting Reports & Gaps
While Health Canada has not linked the deaths to the plasma donation process, the lack of detailed information regarding the incidents has raised concerns. The second deceased donor's identity remains largely unknown, and further investigation is ongoing. Additionally, Grifols is facing a lawsuit from another donor alleging kidney damage due to equipment failure during a donation.
What's Next
Health Canada will continue to monitor Grifols' compliance with the imposed conditions. The House of Commons health committee has requested a copy of the agreement between Grifols and Canadian Blood Services, which is due by April 10, 2026. Grifols is also planning to list its U.S. biopharma unit to raise funds for debt repayment, which may impact its operations in Canada.
Verbatim Quotes
- “There is no correlation between plasma donation and death,” — Mary Hughes, Vice President of Sales, Grifols
- “Health Canada has required corrective actions from Grifols, and will continue to closely monitor progress of the implementation of corrective actions,” — Mark Johnson, Health Canada Spokesperson
- “The secret 15-year contract that the Canadian Blood Services signed with this giant for-profit multinational should be cancelled and plasma collection should revert to the regulated, public, not-for-profit Canadian Blood Services,” — Anne Lagacé Dowson, Canadian Health Coalition Spokesperson
